Overview

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This a double-blind, randomized, placebo-controlled clinical trial to determine if primary prophylaxis with hydroxychloroquine in healthcare workers reduces symptomatic COVID-19 infection. Healthcare workers will be randomized at a 1:1 allocation between intervention and placebo arms and followed for 12 weeks. This study will enroll up to 1,700 participates in Lafayette, Louisiana. The primary outcome will number of symptomatic COVID-19 infections. Secondary endpoints included number of days healthcare workers are absent from work and rate of severe infection.
Phase:
Phase 3
Details
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans
Collaborators:
Lafayette General Health
Lafayette General Medical Center
University of Louisiana at Lafayette
University of Louisiana Lafayette
Treatments:
Hydroxychloroquine